Keeping you up to date on recent developments in cardiology, including: Generating 3D heart organoids; Hostility and heart attacks; Virtual screening tool aims to simplify diagnosing pulmonary hypertension.
LONDON - Scenic Biotech BV has signed up Genentech as first partner for its high-throughput platform for identifying genetic modifiers that can suppress or even completely block the effect of a disease-causing mutated gene, as starting points for drug discovery and development. Under the terms of the agreement, Scenic will identify modifiers in undisclosed therapeutic areas, with Genentech, part of the Roche Group, having an option to take multiple targets into development.
Keeping you up to date on recent developments in neurology, including: New smart drug delivery system may help treatment for neurological disorders; Imaging probe developed for Alzheimer's disease; Potential target identified for migraine therapy.
Researchers at the University of California at San Diego have used RNA-targeted CRISPR to reverse symptoms in an animal model of myotonic dystrophy type 1 (DM1). They reported their findings in the Sept. 14, 2020, issue of Nature Biomedical Engineering.
Keeping you up to date on recent developments in diagnostics, including: Intensive care scoring systems outperform miRNA in sepsis diagnosis; Report: AI falls short of potential in health care; Angiopoietin trouble can lead to lymphedema.
Keeping you up to date on recent developments in orthopedics, including: Restless nature of human spinal cord revealed by noninvasive functional imaging; Stronger bones thanks to heat and microbiota; Researchers use soy to improve bone cancer treatment.
HONG KONG – The Korean 2020 KoNECT-MOHW-MFDS International Conference, which is taking place online this year due to the COVID-19 pandemic, faced a challenging start. Technical difficulties hampered some of the early proceeding. However, technology took focus again later in the day in a more positive, with an exploration of artificial intelligence (AI).
HONG KONG – The use of artificial intelligence in drug discovery was back in the spotlight on the last day of the 2020 KoNECT-MOHW-MFDS International Conference, with drug developers pointing out both challenges and possible solutions.
RSS
